{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:16:35Z","timestamp":1790388995558,"version":"4.1.0"},"reference-count":36,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Introduction: Daptomycin (DAP) is a cyclic lipopeptide that exhibits potent in vitro activity against many drug-resistant gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Despite substantial reports evaluating the clinical outcomes of DAP within the adult population, real-world data are lacking in children. The primary goal of this evaluation was to describe the clinical characteristics and outcomes of DAP use in pediatric patients across a wide range of infections. Methods: This retrospective evaluation included patients &lt; 18 years of age who were treated with DAP from January 2014 to May 2023. The primary objective was to evaluate the composite clinical success, which was defined as a 30-day survival, the lack of a 30-day microbiological recurrence, and the resolution of signs and symptoms of an acute infection without therapy modifications based on clinical failures. Secondary objectives included adverse effects potentially attributable to DAP and reasons for DAP utilization. Results: Forty patients were included, which were predominately male (62.5%) and white (52.5%), with a median age of 8.7 [IQR, 4.4\u201316.0] years. DAP was used for a wide range of infections, including central line-associated bloodstream infections (CLABSIs; 32.5%), infective endocarditis (15.0%), surgical-site infections (12.5%), and osteomyelitis (12.5%). The most common pathogen isolated was MRSA (37.5%), and most patients were bacteremic (60.0%). The median DAP dose was 8 [IQR, 6\u201310] mg\/kg, and the median duration of the DAP therapy was 11.5 [IQR, 4.8\u201318.8] days. Most patients achieved composite clinical success (75.0%). An adverse effect occurred in 5.0% of the patients. DAP was prescribed the most for its ease of use\/ability to facilitate discharge (40.0%) and\/or for issues with alternative therapies (37.5%). Conclusion: Most pediatric patients that received DAP demonstrated clinical success with a low incidence of adverse effects. Larger, real-world studies of DAP use are necessary to further assess clinical outcomes.<\/jats:p>","DOI":"10.3390\/antibiotics13090833","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T09:56:42Z","timestamp":1725357402000},"page":"833","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-World Clinical Characteristics and Outcomes with Daptomycin Use in Pediatric Patients: A Retrospective Case Series"],"prefix":"10.3390","volume":"13","author":[{"given":"Hanna","family":"Persha","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, Medical University of South Carolina Shawn Jenkins Children\u2019s Hospital, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3410-4524","authenticated-orcid":false,"given":"Stephen A.","family":"Thacker","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Infectious Diseases, Medical University of South Carolina Health, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3982-2103","authenticated-orcid":false,"given":"Krutika Mediwala","family":"Hornback","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Medical University of South Carolina, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo R.","family":"Alvira-Arill","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Medical University of South Carolina Shawn Jenkins Children\u2019s Hospital, Charleston, SC 29425, USA"},{"name":"Department of Clinical Pharmacy & Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, SC 29245, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2029-0415","authenticated-orcid":false,"given":"Richard","family":"Lueking","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Medical University of South Carolina Health, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-043X","authenticated-orcid":false,"given":"Taylor","family":"Morrisette","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Medical University of South Carolina Shawn Jenkins Children\u2019s Hospital, Charleston, SC 29425, USA"},{"name":"Department of Pharmacy Services, Medical University of South Carolina, Charleston, SC 29425, USA"},{"name":"Department of Clinical Pharmacy & Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, SC 29245, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1542\/hpeds.2015-0196","article-title":"Rising vancomycin-resistant Enterococcus infections in hospitalized children in the United States","volume":"6","author":"Adams","year":"2016","journal-title":"Hosp. Pediatr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e20153099","DOI":"10.1542\/peds.2015-3099","article-title":"Changing susceptibility of Staphylococcus aureus in a US pediatric population","volume":"137","author":"Sutter","year":"2016","journal-title":"Pediatrics"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1017\/ash.2022.370","article-title":"Trends in pediatric community-onset Staphylococcus aureus antibiotics susceptibilities over a five-year period in a multihospital health system","volume":"3","author":"Prochaska","year":"2023","journal-title":"Antimicrob. Steward. Healthc. Epidemiol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Chiusaroli, L., Liberati, C., Rulli, L., Barbieri, E., De Pieri, M., Chiara, C.D., Mengato, D., Giaquinto, C., and Don\u00e0, D. (2023). Therapeutic options and outcomes for the treatment of children with gram-positive bacteria with resistances of concern: A systematic review. Antibiotics, 12.","DOI":"10.3390\/antibiotics12020261"},{"key":"ref_5","unstructured":"World Health Organization (2024, June 19). WHO Releases Priorities for Research and Development of Age-Appropriate Antibiotics. 24 March 2023. Available online: https:\/\/www.who.int\/news\/item\/24-03-2023-who-releases-priorities-for-research-and-development-of-age-appropriate-antibiotics."},{"key":"ref_6","unstructured":"World Health Organization (2022). Shaping the Global Innovation and Access Landscape for Better Paediatric Medicines: Global Accelerator for Paediatric Formulations 2022\u20132024 Strategy, World Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240044647."},{"key":"ref_7","unstructured":"(2023). Daptomycin [Package Insert], Xellia Pharmaceuticals LLC."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/AAC.44.4.1062-1066.2000","article-title":"In vitro activities of daptomycin, vancomycin, linezolid, and quinopristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains","volume":"44","author":"Rybak","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jac\/dkm170","article-title":"Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: An in vitro and in vivo simulation using historical and current dosing strategies","volume":"60","author":"Rose","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/INF.0b013e318160edfc","article-title":"Single-dose pharmacokinetics of daptomycin in children with suspected or proven gram-positive infections","volume":"27","author":"Benziger","year":"2008","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/tcrm.2006.2.2.169","article-title":"A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections","volume":"2","author":"Shoemaker","year":"2006","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/INF.0000000000001076","article-title":"Clinical experience with daptomycin for the treatment of gram-positive infections in children and adolescents","volume":"35","author":"Syriopoulou","year":"2016","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Papachatzi, E., Gkentzi, D., Tzifas, S., Dassios, T., and Dimitrio, G. (2024). Daptomycin use for persistent coagulase-negative staphylococcal bacteremia in a neonatal intensive care unit. Antibiotics, 13.","DOI":"10.3390\/antibiotics13030254"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/jpids\/piw048","article-title":"Clinical effectiveness, safety profile, and pharmacokinetics of daptomycin in pediatric patients: A systematic review","volume":"5","author":"Karageorgos","year":"2016","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Vonasek, B.J., Samuel, A.M., Henderson, S.L., Strayer, J.R., and Bogenschutz, M.C. (2024). Safety and treatment outcomes of infants and children treated with daptomycin: Six-year experience from a pediatric academic medical center. Clin. Pediatr.","DOI":"10.1177\/00099228241242186"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/jpids\/piad032","article-title":"Time for a change: Considering vancomycin alternatives for pediatric methicillin-resistant Staphylococcus aureus bacteremia","volume":"12","author":"Haynes","year":"2023","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1093\/cid\/cit614","article-title":"Methicillin-resistant Staphylococcus aureus therapy: Past, present, and future","volume":"58","author":"Rodvold","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1086\/519470","article-title":"Limitations of vancomycin in the management of resistant staphylococcal infections","volume":"45","author":"Kollef","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2165\/00003495-200059040-00007","article-title":"Linezolid","volume":"59","author":"Clemett","year":"2000","journal-title":"Drugs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1345\/aph.1R386","article-title":"Clinical relevance of linezolid-associated serotonin toxicity","volume":"47","author":"Woytowish","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"ref_21","unstructured":"(2013). Linezolid [Package Insert], Pfizer."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e20162477","DOI":"10.1542\/peds.2016-2477","article-title":"Daptomycin for complicated skin infections: A randomized trial","volume":"139","author":"Bradley","year":"2017","journal-title":"Pediatrics"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/INF.0000000000001926","article-title":"Randomized multicenter study comparing safety and efficacy of daptomycin versus standard-of-care in pediatric patients with staphylococcal bacteremia","volume":"37","author":"Arrieta","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/INF.0b013e31814523f8","article-title":"Daptomycin therapy for invasive gram-positive bacterial infections in children","volume":"26","author":"Ardura","year":"2007","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jpids\/piu052","article-title":"Daptomycin use in United States children\u2019s hospitals","volume":"4","author":"Larru","year":"2015","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/phar.1872","article-title":"Clinical experience with daptomycin in pediatrics","volume":"37","author":"Namtu","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1128\/AAC.01307-08","article-title":"Relationship between susceptibility to daptomycin in vitro and in vivo activity in a rabbit model of aortic valve endocarditis","volume":"53","author":"Chambers","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1128\/AAC.00102-08","article-title":"Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilies to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations","volume":"52","author":"Rose","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1128\/AAC.06439-11","article-title":"Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic\/pharmacodynamic model with simulated endocardial vegetations","volume":"56","author":"Hall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/phar.2070","article-title":"Association of higher daptomycin dose (7 mg\/kg or greater) with improved survival in patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"38","author":"Timbrook","year":"2018","journal-title":"Pharmacotherapy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/cid\/ciw815","article-title":"Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among veterans affairs patients","volume":"64","author":"Britt","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/INF.0000000000000318","article-title":"Single-dose pharmacokinetics of daptomycin in pediatric patients 3\u201324 months of age","volume":"33","author":"Bradley","year":"2014","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/INF.0b013e31820fc8e1","article-title":"Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg\/kg in children aged 2 to 6 years with suspected or proved gram-positive infections","volume":"30","author":"Chandorkar","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/jcph.2425","article-title":"Daptomycin use optimization in pediatric Staphylococcus aureus bacteremia: A pharmacokinetic\/pharmacodynamic investigation","volume":"64","author":"Olney","year":"2024","journal-title":"J. Clin. Pharmacol."},{"key":"ref_35","unstructured":"CLSI (2024). Performance Standards for Antimicrobial Susceptibility Testing, Clinical and Laboratory Standards Institute. [34th ed.]. CLI Supplement M100."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijid.2008.07.006","article-title":"Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients","volume":"13","author":"Sader","year":"2009","journal-title":"Int. J. Infect. Dis."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/9\/833\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:47:06Z","timestamp":1760111226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/9\/833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["antibiotics13090833"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13090833","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]}}}